Differentiating Alzheimer's Disease from Lewy Body Dementia
The most reliable way to distinguish Alzheimer's disease (AD) from dementia with Lewy bodies (DLB) is to identify the core clinical features of DLB: visual hallucinations, parkinsonism, REM sleep behavior disorder (RBD), and cognitive fluctuations—features that should be absent or minimal in pure AD.
Clinical Feature Algorithm
Core DLB Features (High Specificity)
When evaluating a patient with dementia, systematically assess for these DLB-specific features 1:
- Visual hallucinations: Recurrent, well-formed visual hallucinations are highly predictive of DLB (OR = 31.06) 2
- Parkinsonism: Spontaneous motor features including bradykinesia, rigidity, or rest tremor—gait disturbances are particularly discriminative (OR = 19.32 for DLB vs AD) 2
- REM sleep behavior disorder (RBD): Dream enactment behavior that predates or accompanies cognitive decline (OR = 6.44 for distinguishing mixed DLB/AD from pure AD) 2
- Cognitive fluctuations: Pronounced variations in attention and alertness 3
If two or more of these core features are present alongside dementia, the diagnosis is probable DLB rather than AD 1.
Cognitive Profile Differences
The neuropsychological pattern differs systematically between these conditions:
DLB patients show:
- Relatively preserved memory compared to AD (OR = 3.42) 2
- Better naming ability (OR = 3.35) 2
- Worse processing speed (OR = 0.51) 2
- More prominent visuospatial deficits (OR = 6.06 for visual-spatial complaints) 2
- Reduced smoothness in drawing speed and pressure 4
AD patients show:
- Prominent amnestic presentation: Severe impairment in learning and recall of recently learned information as the earliest and most prominent feature 1
- Relatively preserved processing speed early on
- Less severe visuospatial dysfunction initially
Practical Bedside Test
A simple MMSE-based formula can help: Pentagon-copying score minus Memory recall score (P-M). If P-M = 1 (patient copies pentagons successfully but recalls zero memory words), this has 97% positive predictive value for AD over DLB 5. This reflects AD's early severe memory impairment versus DLB's relative memory preservation with worse visuoconstructional ability.
Important Caveats
Mixed Pathology
Comorbid AD/DLB pathology occurs frequently and complicates diagnosis 6. When both pathologies coexist, patients may show:
- RBD and parkinsonism (suggesting Lewy body component) 2
- More severe memory impairment than pure DLB 2
- Lower depressive symptoms compared to pure DLB (OR = 0.70) 2
Timing Considerations
Do not diagnose probable AD if core DLB features are present 1. The guideline explicitly states that the presence of core DLB features excludes a diagnosis of probable AD, even if amnestic features are prominent.
Depression as a Distinguishing Feature
Increased depressive symptoms favor pure DLB over mixed DLB/AD pathology (OR = 1.44) 2, though this is a supportive rather than core diagnostic feature.
Biomarker Confirmation
When clinical features are ambiguous, biomarkers can clarify:
- Both amyloid and tau biomarkers positive: High likelihood of AD 1
- Alpha-synuclein imaging or dopamine transporter (DAT) scan positive: Supports DLB 7
- Conflicting biomarkers: Suggests mixed pathology 1
The key is that clinical diagnosis should drive initial management decisions, with biomarkers used to increase diagnostic certainty when the clinical picture is unclear 1, 7.